oligoblastic AML


Published on

oligoblastic AML

Published in: Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

oligoblastic AML

  1. 1. Should patients with refractory anemia with excess blasts or those with oligoblastic AML receive induction therapy prior to allogeneic transplantation? Nina Shah Assistant Professor Department of Stem Cell Transplantation M.D. Anderson Cancer Center
  2. 2. Allogeneic Transplant for MDS • The only curative option • Greater experience has made this treatment a reality for older individuals • Traditionally “less disease is better” • But does this hold true for MDS?
  3. 3. The pros of chemo before allo SCT • Historically the fewer blasts (AML) the better • Timing: coordinating the transplant can take 1-2 months
  4. 4. The cons of chemo before transplant • Toxicity • Worsening cytopenias • Infections more delays • No clear prospective data to show benefit • And what about the hypomethylating agents?
  5. 5. Evidence • Nakai et al (Leukemia, 2005) performed a retrospective review of 283 pts who underwent matched related donor allo transplantfor MDS • Compared patients who did and did not receive induction chemotherapy before transplant (RAEB-t or secondary AML) • OS at 5 years was 57% for patients who underwent allo-SCT as a primary treatment and 54% for those who underwent allo-SCT in remission after induction chemotherapy (P=0.81).
  6. 6. Evidence cont. • Scott et al (BBMT 2005) • Retrospective review of 125 pts who underwent related or MUD SCT for MDS or tAML • 33 pts received induction chemo before SCT; 92 did not • No benefit in post-transplant outcomes for those pt who received pre-transplant induction chemotherapy
  7. 7. Hypomethylating agents • Less intense than induction chemotherapy • Higher CR rates with induction chemotherapy IC than with HMAs, although HMAs may be active in patients with complex karyotypes in whom IC almost invariably fails • But patients can still have cytopenias/toxicities • “All interventions aimed at reducing disease burden before allo-SCT expose patients to the risk of complications, which may prevent them from undergoing transplantation” Yakoub-Agha, BBMT 2014
  8. 8. MD Anderson Data • N= 256 pts with MDS undergoing allo SCT after 2001 • 133 matched related, 123 MUD – 78 (30.5%): no pre-SCT therapy – 40 (15.6%) received chemotherapy – 122 (47.7%) received HMA – 16 (6.2%) received both (chemo+HMA) • Outcomes were similar in patients who were untreated and who received cytoreductive therapy before HSCT • Three-year event-free survival (EFS) was 44.2%, 30.6%, 34.2%, and 32.8% respectively, (P = .50) • Monosomal karyotype was a particularly poor prognositc factor Oran, BBMT 2014
  9. 9. OS after allo SCT according to best response to HMA before SCT Oran, Clin Lymph Myel Leuk 2013
  10. 10. Conclusion • Though it is tempting to treat MDS and oligoblastic AML with conventional chemotherapy these diseases may have a different pace from classic AML • The most curative option is allogeneic SCT • There is no prospective evidence that conventional chemotherapy before allo SCT improves patient outcomes • Patients should proceed as quickly as possible to allo SCT